Cellbxhealth Plc · LSE:CLBX
Cellbxhealth — ANGLE — Proactive Investors Event 11 January 2024
18 slides from Cellbxhealth's conference presentation, Jan 11, 2024
Slide 1: Transforming cancer care with the first FDA cleared medical device for CTC capture and harvest
Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumor cells Andrew Newland and Ian Griffiths Proactive Investors Event 11 January 2024
Slide 2: Legal disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: ANGLE – Transforming cancer care
ANGLE – Transforming cancer care Our Mission: Parsortix® instrument Enable personalized cancer care with INTENDED USE a simple blood test to guide The Parsortix® PC1 system is an in vitro diagnostic device treatment, improving patient intended to enrich circulating tumor cells (CTCs) from outcomes a
Slide 4: Parsortix system could address flaws in standard of care
Parsortix system could address flaws in standard of care • NCCN Guidelines recommend biopsies for all metastatic breast cancer patients (MBC) – tissue biopsies from the primary tumor are out-of-date – up-to-date information is needed to select treatment for personalized care – only samples a single
Slide 5: Parsortix system: capturing and harvesting living cancer cells
Parsortix system: capturing and harvesting living cancer cells Plan view Platform technology The Parsortix system harvests cancer cells from blood based on their larger size and lack of deformability. Inlet Other cells can be captured: Outlet • white blood cells associated with the tumor microenviro
Slide 6: Parsortix system patent protected worldwide
Parsortix® system patent protected worldwide • Stepped, microscale cell separators for fluid flow and cell separation • Manufactured under ISO 13485:2016 quality control • Scalable business with third party manufacture • 26 granted patents: United States, Europe, China, Australia, Canada, Japan, Mex
Slide 7: Animation showing operation of Parsortix cassette
Animation showing operation of Parsortix cassette © ANGLE plc 2024 7
Slide 8: Patient blood flowing in Parsortix cassette
Patient blood flowing in Parsortix cassette © ANGLE plc 2024 8
Slide 9: Products - sales and distribution network being established for international penetration
Products - sales and distribution network being established for international penetration • Direct sales team being expanded in United States and UK • Distribution partners selected for other key territories based on: – local knowledge and language – exposure to oncology markets – compliance with qu
Slide 10: Services - differentiated pharma services offering
Services - differentiated pharma services offering • Customer base established and growing Key differentiators – multiple customers, repeat business – new customers in 2024 and growing pipeline • Repeat testing before during and after treatment • Significant revenue and profitability potential • Acc
Slide 11: Services – example customers and active projects
Services – example customers and active projects Global Japanese pharma company • Revenues >£4 billion >10,000 employees • >80 active oncology clinical trials >60,000 participants • HER2 targeting antibody-drug conjugate (ADC) being co-developed by Eisai and Bliss Biopharmaceutical Co., Ltd as part
Slide 12: Content – 'Portrait+' product kit for distribution
Content – ‘Portrait+’ product kit for distribution Antibody kit for robust and consistent imaging by Parsortix customers includes: • Antibodies directly conjugated and mixed into a single vial: – Epithelial markers – Mesenchymal markers – Blood lineage markers • Lyophilised for shipping, storage and
Slide 13: Content – HER2 assay kit in collaboration with BioView
Content – HER2 assay kit in collaboration with BioView • Breast cancer is highly heterogeneous and HER2 status can change over time 80.2% • New antibody-drug conjugates (ADCs) to treat patients with low HER2 status Predicted increase in global cases of breast cancer from 2020 to 2040 • Developing a
Slide 14: Potential breakthrough clinical application: DNA sequencing of CTCs and ctDNA
Potential breakthrough clinical application DNA sequencing of CTCs (living) and ctDNA (dead) © ANGLE plc 2024 14
Slide 15: Content: DNA sequencing of CTCs and ctDNA with Illumina
Content DNA sequencing of CTCs and ctDNA with Illumina • Results from 47 cancer patients DNA variants found in CTCs with FDA cleared drugs for the variants in tissue or • High quality DNA in all samples plasma including • Actionable DNA variants found in CTCs not • PIK3CA (E545K): Alpelisib (Piqray®
Slide 16: Growing body of evidence: leveraged R&D strategy identifying new applications
Growing body of evidence Leveraged R&D strategy identifying new applications • FDA clearance expected to help At 31 December 2023 Parsortix become the CTC system of choice Clinically actionable biomarkers including: 76 published in • Installed base of over 290 Parsortix systems in active use EGFR BR
Slide 17: Near term commercial milestones
Near term commercial milestones • Building services revenues – First large pharma contract secured. Other contract discussions in progress – Roll out of new assays (PD-L1, DDR, HER2 and DNA molecular) providing content for pharma services • Building product revenues – Portrait+ product kit launched
Slide 18: Contact details
ANGLE plc ANGLE Europe Ltd 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom www.angleplc.com Andrew Newland, CEO andrew.newland@angleplc.com Ian Griffiths, CFO i.griffiths@angleplc.com 18